Clinical Trial: Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease
Study Status: NOT_YET_RECRUITING
Recruit Status: NOT_YET_RECRUITING
Condition: Chronic Graft Versus Host Disease
Study Type: INTERVENTIONAL
Official Title: Phase II Trial of Belumosudil and Rituximab for the Primary Treatment of Extensive Chronic Graft-versus-host Disease
Brief Summary:
This is an open-label, Phase 2 study designed to evaluate the safety and efficacy of belumosudil and rituximab as primary treatment of cGVHD.
Read more